e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis
Emily Henkle, Jeffrey R. Curtis, Lang Chen, Benjamin Chan, Timothy R. Aksamit, Charles L. Daley, David E. Griffith, Kevin L. Winthrop
Source:
Eur Respir J, 54 (1) 1801896; 10.1183/13993003.01896-2018
Journal Issue:
July
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Emily Henkle, Jeffrey R. Curtis, Lang Chen, Benjamin Chan, Timothy R. Aksamit, Charles L. Daley, David E. Griffith, Kevin L. Winthrop. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Respir J, 54 (1) 1801896; 10.1183/13993003.01896-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Comparative studies of inhaled corticosteroids in asthma
Source: Eur Respir J 2001; 17: 579-580
Year: 2001
Exacerbations and inhaled corticosteroids in bronchiectasis patients
Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis
Year: 2019
Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis
Source: ERJ Open Res, 8 (1) 00786-2020; 10.1183/23120541.00786-2020
Year: 2022
Rationale for use of inhaled steroids in children with bronchiectasis
Source: International Congress 2019 – Insights into paediatric bronchology
Year: 2019
Risks of pneumonia in asthmatic patients taking inhaled corticosteroids
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations
Source: International Congress 2019 – Severe acute asthma and troublesome wheezing
Year: 2019
Efficacy of systemic corticosteroids in refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β
2
agonist inhalation
Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2010
Effects of inhaled corticosteroids on cough in asthma patients
Source: Eur Respir J 2004; 24: Suppl. 48, 347s
Year: 2004
Anti-inflammatory therapies in bronchiectasis
Source: Eur Respir Mon 2011; 52: 223-238
Year: 2011
Co-dispensing of inhaled corticosteroids and antibiotics
Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care
Year: 2012
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
Source: Eur Respir J 2006; 27: 1168-1174
Year: 2006
Comparison of inhaled corticosteroid combined with theophylline and double-dose inhaled corticosteroid in moderate-severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 127s
Year: 2004
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009
lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005
Effects of montelukast on tapering inhaled corticosteroids in patients with asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 260s
Year: 2001
Effects of montelukast on tapering inhaled corticosteroids in patients with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 407s
Year: 2002
Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016
Year: 2017
Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Inhaled corticosteroids and hospitalisation due to exacerbation of COPD
Source: Eur Respir J 2003; 22: 286-289
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept